ARCHIVES

Ethicists dispute von Eschenbach’s claim that his NCI-FDA conflicts are managed. NCI-FDA chief appears to cite Klausner-era “in-box rule.”

This article is from The Cancer Letter archive.

Vol. 31 No. 46 | December 16, 2005

Download PDF Visit The Full Archive

Related Articles

Procedures For Ending IGs Announced

July 10, 1992

Authorizes $2.7 Billion For NCI, 7% Prevention

May 28, 1993

Samuel Waksal Resigns From ImClone Following Unimpressive ASCO Presentation

May 24, 2002

Studies Test New Agents Offering Relief From Treatment-Related Side Effects

July 30, 2004

“We Will Move Forward With Bold Expectations,” NCI Director Says

October 2, 1998

“Unfortunate Result Of Burzynski’s Practice Over Two Decades: Thousands Of Patients, Not Enough Data” To Determine Safety, Efficacy, FDA Says

September 25, 1998